Status:
COMPLETED
Distribution of Risk Factors in Ocular Hypertension and Open-Angle Glaucoma Patients in Canada
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Glaucoma, Open-Angle
Ocular Hypertension
Eligibility:
All Genders
18+ years
Brief Summary
This descriptive, non-interventional study will collect information on the presence of risk factors in newly diagnosed ocular hypertension and open-angle glaucoma patients in Canada.
Eligibility Criteria
Inclusion
- Subjects diagnosed at study visit or within 3 months of visit with OH
- OAG (to include POAG, NTG, pigmentary and pseudoexfoliation glaucoma)
Exclusion
- No prior treatment for OH or OAG
- No prior ocular surgery or history of ocular trauma
Key Trial Info
Start Date :
November 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2009
Estimated Enrollment :
410 Patients enrolled
Trial Details
Trial ID
NCT00334750
Start Date
November 1 2007
End Date
April 1 2009
Last Update
February 2 2021
Active Locations (21)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Calgary, Alberta, Canada, T3E 7M8
2
Pfizer Investigational Site
Edmonton, Alberta, Canada, T5H 0X5
3
Pfizer Investigational Site
Edmonton, Alberta, Canada, T5H 3V9
4
Pfizer Investigational Site
Nanaimo, British Columbia, Canada, V9R 5B6